Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes
Cancer registries have proven valuable with respect to validating therapeutic safety and drug efficacy, uncovering real-world implementation practices, and their evolution over time. Modern cancer therapeutics are approved as single agents oftentimes compared to the least active approved standard ag...
Main Authors: | Wong, Michael K, Kaufman, Howard L, Daniels, Gregory A, McDermott, David F, Aung, Sandra, Lowder, James N, Morse, Michael A |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100489/ |
Similar Items
-
The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)
by: Kaufman, Howard L., et al.
Published: (2014) -
Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
by: Kaufman, Howard L, et al.
Published: (2014) -
High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates
by: Wong, Michael K, et al.
Published: (2013) -
Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
by: Clark, Joseph I, et al.
Published: (2015) -
Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
by: Wong, Michael KK, et al.
Published: (2015)